MyMD Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 15.2 million compared to USD 29.89 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.85 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.84 USD | +1.07% | +13.60% | -63.41% |
Apr. 18 | MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer | CI |
Apr. 09 | Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data | MT |
1st Jan change | Capi. | |
---|---|---|
-63.41% | 6.13M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MYMD Stock
- News MyMD Pharmaceuticals, Inc.
- MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022